ArticleJCEM case reports2026
Lipoprotein X: artifactual lipid derangement in type 3c diabetes with obstructive liver disease.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein X is an abnormal lipoprotein formed in cholestatic liver disease that causes artifactual elevation of calculated and measured direct low-density lipoprotein cholesterol (LDL-C). A 40-year-old man with chronic pancreatitis presented with hyperglycemic hyperosmolar state secondary to type 3c diabetes. He was jaundiced, with total bilirubin of 9.4 mg/dL (SI: 161 µmol/L) (reference range, 0.3-1.4 mg/dL [SI: 5-24 µmol/L]). Abdominal computed tomography showed severe common bile duct stricturing causing obstructive cholestasis. Laboratory results revealed a physiologically implausible lipid profile: total cholesterol (TC) of 1531 mg/dL (SI: 39.6 mmol/L) (desirable concentration, <200 mg/dL [SI: <5.2 mmol/L]) and direct LDL-C of 1636 mg/dL (SI: 42.3 mmol/L) (desirable concentration, <100 mg/dL [SI: <2.6 mmol/L]). Low-density lipoprotein cholesterol exceeding TC indicated analytical interference. Apolipoprotein B (ApoB) was elevated: 278 mg/dL (SI: 2.78 g/L) (reference range, 66-144 mg/dL [SI: 0.66-1.44 g/L]). The TC:ApoB ratio was 6.9 mmol/g (reference range, 3.8-6.3 mmol/g), supporting coexistent ApoB-negative lipoprotein. Liver and lipid parameters improved post-biliary stenting. ApoB normalized at 6 weeks, supporting a transient, insulin-deficiency-related ApoB-containing lipoprotein excess. Clinicians should suspect lipoprotein X when LDL-C exceeds TC in the setting of cholestasis; if ApoB is also elevated, transient ApoB-mediated dyslipidemia may coexist. Management centers on correcting underlying biliary and metabolic pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.